黄热病疫苗接种后的长期免疫力:系统综述与Meta分析
该系统综述与Meta分析检索11个数据库至2023年8月24日,纳入39项研究共2895名接种单剂黄热病疫苗10-60年者,对20项研究进行随机效应Meta分析。合并血清保护率在非流行区健康成人中为94%(95%CI 86-99),流行区为76%(65-85),儿童为47%(35-60),HIV感染者为61%(38-82)。证据提示单剂疫苗对旅行者提供终生保护,但HIV感染者及2岁以下儿童10年后血清保护比例较低,可能仍需加强接种。
要点
- 单剂黄热病疫苗对非流行区健康成人(多为旅行者)10年以上血清保护率合并为94%。
- 儿童(接种时9-23月龄)和HIV感染者10年以上血清保护率合并分别为47%和61%。
- 流行区居民血清保护率较低部分源于巴西采用更高的血清保护判定阈值。
核心结论
- 证据提示单剂黄热病疫苗对旅行者提供终生保护。
- HIV感染者和2岁以下儿童接种10年及以上后血清保护比例较低,可能仍需加强接种。
- 撒哈拉以南非洲研究稀少且质量低,无法对该地区得出结论。
研究设计与样本
- 系统综述与Meta分析,检索11个数据库自建库至2023年8月24日。
- 纳入报告10年及以上前接种单剂黄热病疫苗的儿童或成人免疫原性结局的队列和横断面研究。
- 排除病例系列和单个病例报告,排除在结局测量前接种超过1剂者。
- 共纳入39项研究,包含2895名10-60年前接种的个体,其中20项研究进入Meta分析。
- 采用非随机干预研究偏倚风险工具和Joanna Briggs研究所分析性横断面研究工具评估偏倚风险,仅纳入中等或高质量研究报告血清保护率进行随机效应Meta分析并按流行性和特定风险组分层。
主要发现
- 非流行区健康成人(多为旅行者)合并血清保护率为94%(95%CI 86-99)。
- 流行区居民(全部为巴西研究)合并血清保护率为76%(65-85)。
- 儿童(接种时9-23月龄)合并血清保护率为47%(35-60)。
- HIV感染者合并血清保护率为61%(38-82)。
- 报告的血清保护判定标准高度异质。
关键数值与推荐
- 非流行区健康成人(多为旅行者)合并血清保护率94%(95%CI 86-99)。
- 流行区居民(全部为巴西研究)合并血清保护率76%(65-85)。
- 儿童(接种时9-23月龄)合并血清保护率47%(35-60)。
- HIV感染者合并血清保护率61%(38-82)。
临床怎么用
- 作者认为单剂黄热病疫苗对旅行者提供终生保护。
- 作者指出HIV感染者和2岁以下儿童接种10年及以上后可能仍需加强接种。
- 流行区居民血清保护率较低部分源于巴西采用更高的血清保护判定阈值。
- 撒哈拉以南非洲研究稀少且质量低,无法对该地区得出结论。
局限性
- 报告的血清保护判定标准高度异质。
- 流行区居民血清保护率较低部分源于巴西采用更高的血清保护判定阈值。
- 撒哈拉以南非洲研究稀少且质量低,无法对该地区得出结论。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Long-term immunity following yellow fever vaccination remains controversial. We aimed to summarise the literature regarding the long-term protection (≥10 years) conveyed by a single dose of yellow fever vaccination. METHODS: In this systematic review and meta-analysis, we searched 11 databases from database inception to Aug 24, 2023. We included cohort and cross-sectional studies reporting immunogenicity outcomes for children or adults who received a single dose of yellow fever vaccination 10 or more years ago. Case series and single case reports were excluded. Participants who received more than one dose of yellow fever vaccination before measurement of the outcome were excluded. Identified records were reviewed by two independent reviewers. The primary outcome of the meta-analysis was the pooled seroprotection rate. Risk of bias was assessed with the Risk Of Bias In Non-randomized Studies of Interventions tool, and the Joanna Briggs Institute tool for analytical cross-sectional studies. Studies of moderate or good quality that reported seroprotection were included for random-effects meta-analysis and stratified by endemicity and specific risk groups. The study was registered with PROSPERO, CRD42023384087. FINDINGS: Of the 7363 articles identified by our search, 39 were eligible for inclusion for systematic review. These studies comprised 2895 individuals vaccinated 10-60 years ago. 20 studies were included in the meta-analysis. Pooled seroprotection rates were 94% (95% CI 86-99) among healthy adults in a non-endemic setting (mostly travellers) and 76% (65-85) in an endemic setting (all Brazilian studies). The pooled seroprotection rate was 47% (35-60) in children (aged 9-23 months at time of vaccination) and 61% (38-82) in people living with HIV. Reported criteria for seroprotection were highly heterogeneous. INTERPRETATION: The gathered evidence suggests that a single dose of yellow fever vaccination provides lifelong protection in travellers. However, in people living with HIV and children (younger than 2 years), booster doses might still be required because lower proportions of vaccinees were seroprotected 10 or more years post-vaccination. Lower observed seroprotection rates among residents of endemic areas were partly explained by the use of a higher cutoff for seroprotection that was applied in Brazil. Studies from sub-Saharan Africa were scarce and of low quality; thus no conclusions could be drawn for this region. FUNDING: None.
引用
- Schnyder JL, de Jong HK, Bache BE, et al. Long-term immunity following yellow fever vaccination: a systematic review and meta-analysis. Lancet Glob Health. 2024. PMID: 38272044. doi:10.1016/S2214-109X(23)00556-9
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。